Abstract
According to data from the World Health Organization (WHO) every year, millions of people are affected by flu. Flu is a disease caused by influenza viruses. For preventing this, seasonal influenza vaccinations are widely considered the most efficient way to protect against the negative effects of the flu. To date, there is no “one-size-fits-all” vaccine that can be effective all over the world to protect against all seasonal or pandemic influenza virus types. Because influenza virus transforms its genetic structure and it can emerges as immunogenically new (antigenic drift) which causes epidemics or new virus subtype (antigenic shift) which causes pandemics. As a result, annual revaccination or new subtype viral vaccine development is required. Currently, three types of vaccines (inactivated, live attenuated, and recombinant) are approved in different countries. These can be named “conventional influenza vaccines” and their production are based on eggs or cell culture. Although, there is good effort to develop new influenza vaccines for broader and longer period of time protection. In this sense these candidate vaccines are called “universal influenza vaccines”. In this article, after we mentioned the short history of flu then virus morphology and infection, we explained the diseases caused by the influenza virus in humans. Afterward, we explained in detail the production methods of available influenza vaccines, types of bioreactors used in cell culture based production, conventional and new vaccine types, and development strategies for better vaccines.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Change history
24 December 2022
An Erratum to this paper has been published: https://doi.org/10.1007/s12257-022-1111-8
References
Barberis, I., P. Myles, S. K. Ault, N. L. Bragazzi, and M. Martini (2016) History and evolution of influenza control through vaccination: from the first monovalent vaccine to universal vaccines. J. Prev. Med. Hyg. 57: E115–E120.
Moghadami, M. (2017) A narrative review of influenza: a seasonal and pandemic disease. Iran. J. Med. Sci. 42: 2–13.
Khanna, M., L. Saxena, A. Gupta, B. Kumar, and R. Rajput (2013) Influenza pandemics of 1918 and 2009: a comparative account. Future Virol. 8: 335–342.
Harrington, W. N., C. M. Kackos, and R. J. Webby (2021) The evolution and future of influenza pandemic preparedness. Exp. Mol. Med. 53: 737–749.
Cox, R. J., K. A. Brokstad, and P. Ogra (2004) Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand. J. Immunol. 59: 1–15.
Paules, C. and K. Subbarao (2017) Influenza. Lancet 390: 697–708.
Hayden, F. G. and P. Palese (2016) Influenza virus. pp. 1009–1058. In: D. D. Richman, R. J. Whitley, and F. J. Hayden (eds.). Clinical Virology. 4th ed. ASM Press, Washington, DC, USA.
Du, R., Q. Cui, and L. Rong (2019) Competitive cooperation of hemagglutinin and neuraminidase during influenza A virus entry. Viruses 11: 458.
Mostafa, A., E. M. Abdelwhab, T. C. Mettenleiter, and S. Pleschka (2018) Zoonotic potential of influenza A viruses: a comprehensive overview. Viruses. 10: 497.
Vemula, S. V., J. Zhao, J. Liu, X. Wang, S. Biswas, and I. Hewlett (2016) Current approaches for diagnosis of influenza virus infections in humans. Viruses. 8: 96.
Kim, P., Y. H. Jang, S. B. Kwon, C. M. Lee, G. Han, and B. L. Seong (2018) Glycosylation of hemagglutinin and neuraminidase of influenza A virus as signature for ecological spillover and adaptation among influenza reservoirs. Viruses. 10: 183.
Krammer, F. (2019) The human antibody response to influenza A virus infection and vaccination. Nat. Rev. Immunol. 19: 383–397.
Bresee, J. S., A. M. Fry, S. Sambhara, and N. J. Cox (2018) Inactivated influenza vaccines. pp. 456–488.e21. In: S. A. Plotkin, W. A. Orenstein, P. A. Offit, and K. M. Edwards (eds.). Plotkin’s Vaccines. 7th ed. Elsevier, Philadelphia, PA, USA.
Sun, W., T. Luo, W. Liu, and J. Li (2020) Progress in the development of universal influenza vaccines. Viruses. 12: 1033.
Nachbagauer, R. and P. Palese (2020) Is a universal influenza virus vaccine possible? Annu. Rev. Med. 71: 315–327.
Vogel, O. A. and B. Manicassamy (2020) Broadly protective strategies against influenza viruses: universal vaccines and therapeutics. Front. Microbiol. 11: 135.
CDC, Types of influenza viruses. https://www.cdc.gov/flu/about/viruses/types.htm.
Forst, C. V. (2012) Influenza infection and therapy: a systems approach. Future Virol. 7: 973–988.
Javanian, M., M. Barary, S. Ghebrehewet, V. Koppolu, V. K. R. Vasigala, and S. Ebrahimpour (2021) A brief review of influenza virus infection. J. Med. Virol. 93: 4638–4646.
Rioux, M., M. McNeil, M. E. Francis, N. Dawe, M. Foley, J. M. Langley, and A. A. Kelvin (2020) The power of first impressions: can influenza imprinting during infancy inform vaccine design? Vaccines (Basel). 8: 546.
Nyirenda, M., R. Omori, H. L. Tessmer, H. Arimura, and K. Ito (2016) Estimating the lineage dynamics of human influenza B viruses. PLoS One. 11: e0166107.
Francis, M. E., M. L. King, and A. A. Kelvin (2019) Back to the future for influenza preimmunity-looking back at influenza virus history to infer the outcome of future infections. Viruses. 11: 122.
Wei, C. J., M. C. Crank, J. Shiver, B. S. Graham, J. R. Mascola, and G. J. Nabel (2020) Next-generation influenza vaccines: opportunities and challenges. Nat. Rev. Drug Discov. 19: 239–252. (Erratum published 2020, Nat. Rev. Drug Discov. 19: 427)
McAuley, J. L., B. P. Gilbertson, S. Trifkovic, L. E. Brown, and J. L. McKimm-Breschkin (2019) Influenza virus neuraminidase structure and functions. Front. Microbiol. 10: 39.
Jung, H. E. and H. K. Lee (2020) Host protective immune responses against influenza A virus infection. Viruses. 12: 504.
Bouvier, N. M. and P. Palese (2008) The biology of influenza viruses. Vaccine. 26: D49–D53.
Luke, C. J., S. S. Lakdawala, and K. Subbarao (2018) Influenza vaccine-live. pp. 489–510.e7. In: S. A. Plotkin, W. A. Orenstein, P. A. Offit, and K. M. Edwards (eds.). Plotkin’s Vaccines. 7th ed. Elsevier, Philadelphia, PA, USA.
Dadonaite, B., S. Vijayakrishnan, E. Fodor, D. Bhella, and E. C. Hutchinson (2016) Filamentous influenza viruses. J. Gen. Virol. 97: 1755–1764.
Spitaels, J., K. Roose, and X. Saelens (2016) Influenza and memory T cells: how to awake the force. Vaccines (Basel). 4: 33.
de Vries, E., W. Du, H. Guo, and C. A. M. de Haan (2020) Influenza A virus hemagglutinin-neuraminidase-receptor balance: preserving virus motility. Trends Microbiol. 28: 57–67.
Kosik, I. and J. W. Yewdell (2019) Influenza hemagglutinin and neuraminidase: yin-yang proteins coevolving to thwart immunity. Viruses. 11: 346.
Herold, S., C. Becker, K. M. Ridge, and G. R. S. Budinger (2015) Influenza virus-induced lung injury: pathogenesis and implications for treatment. Eur. Respir. J. 45: 1463–1478.
Walker, A. P. and E. Fodor (2019) Interplay between influenza virus and the host RNA polymerase II transcriptional machinery. Trends Microbiol. 27: 398–407.
Te Velthuis, A. J. W. and E. Fodor (2016) Influenza virus RNA polymerase: insights into the mechanisms of viral RNA synthesis. Nat. Rev. Microbiol. 14: 479–493.
van de Sandt, C. E., J. H. C. M. Kreijtz, and G. F. Rimmelzwaan (2012) Evasion of influenza A viruses from innate and adaptive immune responses. Viruses. 4: 1438–1476.
Kreijtz, J. H. C. M., R. A. M. Fouchier, and G. F. Rimmelzwaan (2011) Immune responses to influenza virus infection. Virus Res. 162: 19–30.
Iwasaki, A. and P. S. Pillai (2014) Innate immunity to influenza virus infection. Nat. Rev. Immunol. 14: 315–328.
Atkin-Smith, G. K., M. Duan, W. Chen, and I. K. H. Poon (2018) The induction and consequences of Influenza A virus-induced cell death. Cell Death Dis. 9: 1002.
Lee, Y. T., K. H. Kim, E. J. Ko, Y. N. Lee, M. C. Kim, Y. M. Kwon, Y. Tang, M. K. Cho, Y. J. Lee, and S. M. Kang (2014) New vaccines against influenza virus. Clin. Exp. Vaccine Res. 3: 12–28.
WHO Global Influenza Programme, Recommendations for influenza vaccine composition. https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations.
Grohskopf, L. A., E. Alyanak, K. R. Broder, L. H. Blanton, A. M. Fry, D. B. Jernigan, and R. L. Atmar (2020) Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices — United States, 2020–21 influenza season. MMWR Recomm. Rep. 69: 1–24.
Yamayoshi, S. and Y. Kawaoka (2019) Current and future influenza vaccines. Nat. Med. 25: 212–220.
ECDC, Types of seasonal influenza vaccines. https://www.ecdc.europa.eu/en/seasonal-influenza/prevention-and-control/vaccines/types-of-seasonal-influenza-vaccine.
FDA, Vaccines Licensed for Use in the United States. https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states.
FDA, Influenza Vaccine for the 2021–2022 Season. https://www.fda.gov/vaccines-blood-biologics/lot-release/influenza-vaccine-2021-2022-season.
CDC, Influenza vaccines — United States, 2021–22 influenza season. https://www.cdc.gov/flu/professionals/acip/2021-2022/aciptable.htm.
EMA, Medicines Online Database. https://www.ema.europa.eu/en/medicines?search_api_views_fulltext=influenza+vaccine.
Wu, Y., H. Jia, H. Lai, X. Liu, and W.-S. Tan (2020) Highly efficient production of an influenza H9N2 vaccine using MDCK suspension cells. Bioresour. Bioprocess. 7: 63.
Madsen, A. and R. J. Cox (2020) Prospects and challenges in the development of universal influenza vaccines. Vaccines (Basel). 8: 361.
Soema, P. C., R. Kompier, J. P. Amorij, and G. F. A. Kersten (2015) Current and next generation influenza vaccines: formulation and production strategies. Eur. J. Pharm. Biopharm. 94: 251–263.
Bardiya, N. and J. H. Bae (2005) Influenza vaccines: recent advances in production technologies. Appl. Microbiol. Biotechnol. 67: 299–305.
Chen, J. R., Y. M. Liu, Y. C. Tseng, and C. Ma (2020) Better influenza vaccines: an industry perspective. J. Biomed. Sci. 27: 33.
Krammer, F. and P. Palese (2015) Advances in the development of influenza virus vaccines. Nat. Rev. Drug Discov. 14: 167–182. (Erratum published 2015, Nat. Rev. Drug Discov. 14: 294)
Rajaram, S., C. Boikos, D. K. Gelone, and A. Gandhi (2020) Influenza vaccines: the potential benefits of cell-culture isolation and manufacturing. Ther. Adv. Vaccines Immunother. 8: 2515135520908121.
Nogales, A. and L. Martínez-Sobrido (2017) Reverse genetics approaches for the development of influenza vaccines. Int. J. Mol. Sci. 18: 20.
Lewnard, J. A. and S. Cobey (2018) Immune history and influenza vaccine effectiveness. Vaccines (Basel). 6: 28.
Lambert, L. C. and A. S. Fauci (2010) Influenza vaccines for the future. N. Engl. J. Med. 363: 2036–2044.
Sedova, E. S., D. N. Shcherbinin, A. I. Migunov, I. A. Smirnov, D. I. Logunov, M. M. Shmarov, L. M. Tsybalova, B. S. Naroditskiĭ, O. I. Kiselev, and A. L. Gintsburg (2012) Recombinant influenza vaccines. Acta Naturae. 4: 17–27.
Pica, N. and P. Palese (2013) Toward a universal influenza virus vaccine: prospects and challenges. Annu. Rev. Med. 64: 189–202.
Kumar, A., T. S. Meldgaard, and S. Bertholet (2018) Novel platforms for the development of a universal influenza vaccine. Front. Immunol. 9: 600.
Ostrowsky, J., M. Arpey, K. Moore, M. Osterholm, M. Friede, J. Gordon, D. Higgins, J. Molto-Lopez, J. Seals, and J. Bresee (2020) Tracking progress in universal influenza vaccine development. Curr. Opin. Virol. 40: 28–36.
Henry, C., A. K. E. Palm, F. Krammer, and P. C. Wilson (2018) From original antigenic sin to the universal influenza virus vaccine. Trends Immunol. 39: 70–79.
National Institutes of Health (NIH) United States National Library of Medicine, Clinical Trials Database. URL: https://clinicaltrials.gov.
Tripp, R. A. and S. M. Tompkins (2014) Virus-vectored influenza virus vaccines. Viruses. 6: 3055–3079.
Malonis, R. J., J. R. Lai, and O. Vergnolle (2020) Peptide-based vaccines: current progress and future challenges. Chem. Rev. 120: 3210–3229.
Al-Halifa, S., L. Gauthier, D. Arpin, S. Bourgault, and D. Archambault (2019) Nanoparticle-based vaccines against respiratory viruses. Front. Immunol. 10: 22.
Pérez Rubio, A. and J. M. Eiros (2018) Cell culture-derived flu vaccine: present and future. Hum. Vaccin. Immunother. 14: 1874–1882.
Manini, I., C. M. Trombetta, G. Lazzeri, T. Pozzi, S. Rossi, and E. Montomoli (2017) Egg-independent influenza vaccines and vaccine candidates. Vaccines (Basel). 5: 18.
Trombetta, C. M., S. Marchi, I. Manini, G. Lazzeri, and E. Montomoli (2019) Challenges in the development of egg-independent vaccines for influenza. Expert Rev. Vaccines. 18: 737–750.
Genzel, Y. (2015) Designing cell lines for viral vaccine production: where do we stand? Biotechnol. J. 10: 728–740.
Milián, E. and A. A. Kamen (2015) Current and emerging cell culture manufacturing technologies for influenza vaccines. Biomed. Res. Int. 2015: 504831.
Audsley, J. M. and G. A. Tannock (2008) Cell-based influenza vaccines: progress to date. Drugs. 68: 1483–1491.
Gallo-Ramírez, L. E., A. Nikolay, Y. Genzel, and U. Reichl (2015) Bioreactor concepts for cell culture-based viral vaccine production. Expert Rev. Vaccines. 14: 1181–1195.
Shukla, A. A. and U. Gottschalk (2013) Single-use disposable technologies for biopharmaceutical manufacturing. Trends Biotechnol. 31: 147–154.
Tapia, F., D. Wohlfarth, V. Sandig, I. Jordan, Y. Genzel, and U. Reichl (2019) Continuous influenza virus production in a tubular bioreactor system provides stable titers and avoids the “von Magnus effect”. PLoS One. 14: e0224317.
Genzel, Y., C. Dietzsch, E. Rapp, J. Schwarzer, and U. Reichl (2010) MDCK and Vero cells for influenza virus vaccine production: a one-to-one comparison up to lab-scale bioreactor cultivation. Appl. Microbiol. Biotechnol. 88: 461–475.
Lohr, V., Y. Genzel, I. Behrendt, K. Scharfenberg, and U. Reichl (2010) A new MDCK suspension line cultivated in a fully defined medium in stirred-tank and wave bioreactor. Vaccine. 28: 6256–6264.
Gränicher, G, J. Coronel, A. Pralow, P. Marichal-Gallardo, M. Wolff, E. Rapp, A. Karlas, V. Sandig, Y. Genzel, and U. Reichl (2019) Efficient influenza A virus production in high cell density using the novel porcine suspension cell line PBG.PK2.1. Vaccine. 37: 7019–7028.
Genzel, Y., I. Behrendt, J. Rödig, E. Rapp, C. Kueppers, S. Kochanek, G. Schiedner, and U. Reichl (2013) CAP, a new human suspension cell line for influenza virus production. Appl. Microbiol. Biotechnol. 97: 111–122.
Peschel, B., S. Frentzel, T. Laske, Y. Genzel, and U. Reichl (2013) Comparison of influenza virus yields and apoptosis-induction in an adherent and a suspension MDCK cell line. Vaccine. 31: 5693–5699.
Petiot, E., A. Proust, A. Traversier, L. Durous, F. Dappozze, M. Gras, C. Guillard, J. M. Balloul, and M. Rosa-Calatrava (2018) Influenza viruses production: evaluation of a novel avian cell line DuckCelt®-T17. Vaccine. 36: 3101–3111.
Petiot, E., D. Jacob, S. Lanthier, V. Lohr, S. Ansorge, and A. A. Kamen (2011) Metabolic and kinetic analyses of influenza production in perfusion HEK293 cell culture. BMC Biotechnol. 11: 84.
Wu, Y., T. Bissinger, Y. Genzel, X. Liu, U. Reichl, and W. S. Tan (2021) High cell density perfusion process for high yield of influenza A virus production using MDCK suspension cells. Appl. Microbiol. Biotechnol. 105: 1421–1434. (Erratum published 2021, Appl. Microbiol. Biotechnol. 105: 4341)
Coronel, J., G. Gränicher, V. Sandig, T. Noll, Y. Genzel, and U. Reichl (2020) Application of an inclined settler for cell culture-based influenza A virus production in perfusion mode. Front. Bioeng. Biotechnol. 8: 672.
Le Ru, A., D. Jacob, J. Transfiguracion, S. Ansorge, O. Henry, and A. A. Kamen (2010) Scalable production of influenza virus in HEK-293 cells for efficient vaccine manufacturing. Vaccine. 28: 3661–3671.
Pau, M. G., C. Ophorst, M. H. Koldijk, G. Schouten, M. Mehtali, and F. Uytdehaag (2001) The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines. Vaccine. 19: 2716–2721.
Lohr, V., Y. Genzel, I. Jordan, D. Katinger, S. Mahr, V. Sandig, and U. Reichl (2012) Live attenuated influenza viruses produced in a suspension process with avian AGE1.CR.pIX cells. BMC Biotechnol. 12: 79.
Hu, A. Y. C., Y. F. Tseng, T. C. Weng, C. C. Liao, J. Wu, A. H. Chou, H. J. Chao, A. Gu, J. Chen, S. C. Lin, C. H. Hsiao, S. C. Wu, and P. Chong (2011) Production of inactivated influenza H5N1 vaccines from MDCK cells in serum-free medium. PLoS One. 6: e14578.
Genzel, Y., R. M. Olmer, B. Schäfer, and U. Reichl (2006) Wave microcarrier cultivation of MDCK cells for influenza virus production in serum containing and serum-free media. Vaccine. 24: 6074–6087.
Perrin, P., S. Madhusudana, C. Gontier-Jallet, S. Petres, N. Tordo, and O. W. Merten (1995) An experimental rabies vaccine produced with a new BHK-21 suspension cell culture process: use of serum-free medium and perfusion-reactor system. Vaccine. 13: 1244–1250.
Coronel, J., I. Behrendt, T. Bürgin, T. Anderlei, V. Sandig, U. Reichl, and Y. Genzel (2019) Influenza A virus production in a single-use orbital shaken bioreactor with ATF or TFF perfusion systems. Vaccine. 37: 7011–7018.
Nikolay, A., A. Léon, K. Schwamborn, Y. Genzel, and U. Reichl (2018) Process intensification of EB66® cell cultivations leads to high-yield yellow fever and Zika virus production. Appl. Microbiol. Biotechnol. 102: 8725–8737.
Genzel, Y., T. Vogel, J. Buck, I. Behrendt, D. V. Ramirez, G. Schiedner, I. Jordan, and U. Reichl (2014) High cell density cultivations by alternating tangential flow (ATF) perfusion for influenza A virus production using suspension cells. Vaccine. 32: 2770–2781.
Vázquez-Ramírez, D., Y. Genzel, I. Jordan, V. Sandig, and U. Reichl (2018) High-cell-density cultivations to increase MVA virus production. Vaccine. 36: 3124–3133.
Chen, Y. H., J. C. Wu, K. C. Wang, Y. W. Chiang, C. W. Lai, Y. C. Chung, and Y. C. Hu (2005) Baculovirus-mediated production of HDV-like particles in BHK cells using a novel oscillating bioreactor. J. Biotechnol. 118: 135–147.
Lu, J. T., Y. C. Chung, Z. R. Chan, and Y. C. Hu (2005) A novel oscillating bioreactor BelloCell: implications for insect cell culture and recombinant protein production. Biotechnol. Lett. 27: 1059–1065.
Lai, C. C., T. C. Weng, Y. F. Tseng, J. R. Chiang, M. S. Lee, and A. Y. C. Hu (2019) Evaluation of novel disposable bioreactors on pandemic influenza virus production. PLoS One. 14: e0220803.
Tapia, F., T. Vogel, Y. Genzel, I. Behrendt, M. Hirschel, J. D. Gangemi, and U. Reichl (2014) Production of high-titer human influenza A virus with adherent and suspension MDCK cells cultured in a single-use hollow fiber bioreactor. Vaccine. 32: 1003–1011.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
The authors declare no conflict of interest.
Neither ethical approval nor informed consent was required for this study.
Additional information
Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Demirden, S.F., Alptekin, K., Kimiz-Gebologlu, I. et al. Influenza Vaccine: An Engineering Vision from Virological Importance to Production. Biotechnol Bioproc E 27, 740–764 (2022). https://doi.org/10.1007/s12257-022-0115-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12257-022-0115-8